BioNTech to Close Tübingen Site by End of 2027, Impacting Over 700 Jobs

BioNTech has confirmed it will shut down its Tübingen site by the end of 2027, a decision driven by sharply reduced demand for COVID-19 vaccines and their failure to find an investor interested in maintaining operations there. This closure will affect more than 700 employees, raising concerns about the future of the biotech sector in the region.

Tübingen’s Mayor Boris Palmer voiced his disappointment, underscoring the biotech industry’s crucial role for the local economy and expressing worries over pandemic preparedness amid the shutdown. The planned closure signals a significant shift in BioNTech’s strategy, reflecting changing market dynamics post-pandemic.

The move coincides with other regional developments: Stuttgart airport is set to receive €2.3 million to improve eco-friendly ground operations, and transportation strikes are scheduled from September 30 to October 2, further complicating local logistics.

The closure raises important questions about job security for hundreds of skilled workers and the region’s ability to sustain a vibrant biotech ecosystem. BioNTech’s decision highlights the challenges faced by pandemic-related industries as demand normalizes.

Looking ahead, it remains to be seen how the site’s shutdown will influence Tübingen’s economic landscape and if any measures will be taken to mitigate the employment impact. Meanwhile, the local authorities continue to express concerns regarding preparedness for future health crises.